Eli Lilly and Company (NYSE:LLY) Shares Sold by SkyOak Wealth LLC

SkyOak Wealth LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 3.4% in the fourth quarter, Holdings Channel reports. The fund owned 24,439 shares of the company’s stock after selling 873 shares during the period. Eli Lilly and Company accounts for approximately 3.7% of SkyOak Wealth LLC’s investment portfolio, making the stock its 6th largest holding. SkyOak Wealth LLC’s holdings in Eli Lilly and Company were worth $14,246,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of LLY. JGP Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares during the last quarter. Cassia Capital Partners LLC increased its position in shares of Eli Lilly and Company by 1.8% in the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock valued at $511,000 after purchasing an additional 17 shares during the last quarter. Walkner Condon Financial Advisors LLC boosted its position in shares of Eli Lilly and Company by 2.8% during the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after acquiring an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC raised its holdings in Eli Lilly and Company by 2.8% during the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after purchasing an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. lifted its position in Eli Lilly and Company by 1.3% in the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after acquiring an additional 17 shares during the last quarter. Institutional investors and hedge funds own 81.38% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. BMO Capital Markets raised their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Finally, Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $689.52.

Eli Lilly and Company Trading Up 0.0 %

NYSE LLY traded up $0.04 during mid-day trading on Friday, reaching $770.30. 1,979,787 shares of the stock were exchanged, compared to its average volume of 3,298,234. Eli Lilly and Company has a 1-year low of $323.26 and a 1-year high of $800.78. The business’s fifty day simple moving average is $720.00 and its 200 day simple moving average is $630.77. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market capitalization of $731.91 billion, a PE ratio of 132.86, a PEG ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period last year, the business posted $2.09 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 195,055 shares of company stock worth $125,254,657. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.